Chronic liver disease affects 1.5 billion people globally, of whom 18.3% are of Indian origin, indicating a significant liver ...
JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company ...
DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic Applied BioSolutions, Inc. (NASDAQ: DYAI) announced 2025 results on March 25 th , 2026, and held a conference call providing additional detail after that ...
Albumin triggers fungal virulence: Candida albicans forms denser biofilms in the presence of human albumin (right) compared to its absence (left), revealing a hidden pathogenicity pathway. Candida ...
Albumin is a major prognostic factor for patients with advanced liver disease, dependent on its concentration and biological activity. This study aimed to improve the method of active albumin ...
In a multicenter randomized clinical trial of 440 patients with septic shock, albumin replacement therapy targeting serum levels ≥ 3.0 g/dL did not reduce 90-day mortality compared with standard ...
Commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExp ...
Explore how time-resolved fluorescence enables sensitive monitoring of dye–protein binding in microliter volumes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results